MolecularMD grants Ariad a license to a companion diagnostic for Ariad's cancer candidate ponatinib

MolecularMD Corp.

U.S. / Tools, Services, and Manufacturing

Licensor

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Ariad Pharmaceuticals Inc.

U.S. / Mid-Cap Biopharma ($1-$50 billion)

$880.7m on 03/25/2011 [market cap]

Licensee

This is a sample profile. To view the full content of this profile and many others, log in to BCIQ or sign up for a free trial today!

Active

Sample

01/01/2009

announced